Page 13 - Diagnostic Test News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Startups fight COVID-19: Pune-based Mylab continues to develop innovative solutions to combat second wave To fight the second wave of COVID-19, Pune-based Mylab Discovery Solutions is working on multiple innovative solutions. The startup has already launched a fleet of mobile labs to meet increasing demands for testing. 0 claps Share on India is in the middle of a deadly second wave of COVID-19, which is infecting more people with each passing day. As of Sunday, the total number of cases of COVID-19 infection in India stands at 17 million. And once again, the Indian startup ecosystem is gea...

Government has secured about forty eighty million united states dollars USD 47.28m, from the Global fund for Covid-19 response. Health Minister Jonas Chanda who has confirmed the development says an additionally, his ministry has also received committed US $ 20 million united States dollars from the United States President ‘s Emergency Plan for AIDs Relief ( PEPFAR ) for the Covid-19 response, respectively. Dr Chanda discloses that about Ten thousand, 10,000 Genexpert cartridges and over four thousand , 4,000 Rapid Diagnostic Test (RDTs) kits are expected in the country. The minister says a...

Philip Cheung / The New York Times / Redux The coronavirus pandemic may be in its final stage in the U.S. But it will not be the last pandemic of the 21st century. Since the turn of the century, SARS-CoV-2 is already the second virus to create a pandemic (the first was the H1N1 influenza in 2009) and the third coronavirus outbreak, following the first SARS crisis in 2003 and the emergence of Middle Eastern Respiratory Syndrome, also known as MERS, in 2012. If the U.S. can expect roughly one global plague every 10 years, it will have to do better than it did over the past 12 months, when it sh...

Federal rules restrict labs from telling patients and their doctors if they've been infected by a COVID variant.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies. (*Complementary when referring to the US regulatory pathway.)